Associations of Plasma and CSF Osteocalcin Levels With CSF ATN Biomarkers and Cognitive Functions in Alzheimer's Disease

Abstract

Animal studies have shown that osteocalcin (OCN), a hormone derived from bone, plays a vital role in brain development and cognitive function. However, its potential connection to Alzheimer's disease (AD) pathology in humans remains largely unexplored. This cross-section study included 238 cognitively unimpaired participants, 26 mild cognitive impairment (MCI) patients, 54 AD dementia patients, and 32 patients with non-AD neurodegenerative diseases. Plasma and cerebrospinal fluid (CSF) levels of OCN were measured by enzyme-linked immunosorbent assay kits. In the clinical diagnosis-based subgroup, plasma and CSF levels of OCN were significantly higher in MCI and AD dementia compared with cognitively unimpaired participants. In the ATN framework-based subgroup, plasma and CSF OCN levels were significantly elevated in Aβ-positive participants, including those in the preclinical stage of AD. Both plasma and CSF OCN levels were negatively correlated with CSF Aβ42 and positively correlated with CSF total-tau and phosphorylated-tau181/Aβ42. In addition, OCN mediated the relationship between Aβ pathology and tau pathology. Notably, OCN levels in plasm and CSF were also negatively associated with cognitive functions. This study provides clinical evidence linking OCN to AD, suggesting that OCN may be associated with brain Aβ deposition, tau hyperphosphorylation and neurodegeneration.

Keywords

alzheimer's disease / amyloid-beta / cognitive function / osteocalcin / tau

References

[1] 2024 Alzheimer's Disease Facts and Figures. Alzheimers Dement 2024; 20(5): 3708-3821.

[2] P. Scheltens, B. De Strooper, M. Kivipelto, et al., “Alzheimer's Disease,” Lancet 397, no. 10284 (2021): 1577-1590.

[3] J. Xiong, Z. Zhang, and K. Ye, “C/EBPβ/AEP Signaling Drives Alzheimer's Disease Pathogenesis,” Neurosci Bull 39, no. 7 (2023): 1173-1185.

[4] J. V. Pluvinage and T. Wyss-Coray, “Systemic Factors as Mediators of Brain Homeostasis, Ageing and Neurodegeneration,” Nature Reviews Neuroscience 21, no. 2 (2020): 93-102.

[5] J. Wang, B. J. Gu, C. L. Masters, and Y. J. Wang, “A Systemic View of Alzheimer Disease—insights From Amyloid-beta Metabolism Beyond the Brain,” Nature reviews Neurology 13, no. 10 (2017): 612-623.

[6] H. L. Sun, S. H. Chen, Z. Y. Yu, et al., “Blood Cell-produced Amyloid-beta Induces Cerebral Alzheimer-type Pathologies and Behavioral Deficits,” Molecular Psychiatry 26, no. 10 (2021): 5568-5577.

[7] Z. H. Liu, Y. J. Wang, and X. L. Bu, “Alzheimer's Disease: Targeting the Peripheral Circulation,” Mol Neurodegener 18, no. 1 (2023): 3.

[8] H. Chen, D. Shang, Y. Wen, and C. Liang, “Bone-Derived Modulators That Regulate Brain Function: Emerging Therapeutic Targets for Neurological Disorders,” Frontiers in Cell and Developmental Biology 9 (2021): 683457.

[9] J. Yuan, B. P. Meloni, T. Shi, et al., “The Potential Influence of Bone-Derived Modulators on the Progression of Alzheimer's Disease,” Journal of Alzheimer's Disease 69, no. 1 (2019): 59-70.

[10] Y. L. Jiang, Z. X. Wang, X. X. Liu, et al., “The Protective Effects of Osteocyte-Derived Extracellular Vesicles against Alzheimer's Disease Diminished With Aging,” Adv Sci (Weinh) 9, no. 17 (2022): e2105316.

[11] F. Oury, L. Khrimian, C. A. Denny, et al., “Maternal and Offspring Pools of Osteocalcin Influence Brain Development and Functions,” Cell 155, no. 1 (2013): 228-241.

[12] L. Khrimian, A. Obri, M. Ramos-Brossier, et al., “Gpr158 mediates osteocalcin's Regulation of Cognition,” Journal of Experimental Medicine 214, no. 10 (2017): 2859-2873.

[13] Z. Qian, H. Li, H. Yang, et al., “Osteocalcin Attenuates Oligodendrocyte Differentiation and Myelination via GPR37 Signaling in the Mouse Brain,” Science Advances 7, no. 43 (2021): eabi5811.

[14] X.-Z. Guo, C. Shan, Y.-F. Hou, et al., “Osteocalcin Ameliorates Motor Dysfunction in a 6-Hydroxydopamine-Induced Parkinson's Disease Rat Model through AKT/GSK3β Signaling,” Front Mol Neurosci 11 (2018): 343.

[15] Y.-F. Hou, C. Shan, S.-Y. Zhuang, et al., “Gut Microbiota-derived Propionate Mediates the Neuroprotective Effect of osteocalcin in a Mouse Model of Parkinson's disease,” Microbiome 9, no. 1 (2021): 34.

[16] A. Obri, L. Khrimian, G. Karsenty, and F. Oury, “Osteocalcin in the Brain: From Embryonic Development to Age-related Decline in Cognition,” Nature reviews Endocrinology 14, no. 3 (2018): 174-182.

[17] R. Zhou, H. Zhou, L. Rui, and J. Xu, “Bone Loss and Osteoporosis Are Associated With Conversion From Mild Cognitive Impairment to Alzheimer's Disease,” Curr Alzheimer Res 11, no. 7 (2014): 706-713.

[18] M. J. Kwon, J. H. Kim, J. H. Kim, S. J. Cho, E. S. Nam, and H. G. Choi, “The Occurrence of Alzheimer's Disease and Parkinson's Disease in Individuals With Osteoporosis: A Longitudinal Follow-Up Study Using a National Health Screening Database in Korea,” Frontiers in aging neuroscience 13 (2021): 786337.

[19] K. Kostev, P. Hadji, and L. Jacob, “Impact of Osteoporosis on the Risk of Dementia in Almost 60,000 Patients Followed in General Practices in Germany,” Journal of Alzheimer's Disease 65, no. 2 (2018): 401-407.

[20] S. Kosmidis, A. Polyzos, L. Harvey, et al., “RbAp48 Protein Is a Critical Component of GPR158/OCN Signaling and Ameliorates Age-Related Memory Loss,” Cell reports 25, no. 4 (2018): 959-973.

[21] X. Guo, Y. Y. Yang, R. Zhou, et al., “Causal Effect of Blood Osteocalcin on the Risk of Alzheimer's Disease and the Mediating Role of Energy Metabolism,” Transl Psychiatry 14, no. 1 (2024): 205.

[22] W. Liu, Q. Hu, F. Zhang, K. Shi, and J. Wu, “Investigation of the Causal Relationship Between Osteocalcin and Dementia: A Mendelian Randomization Study,” Heliyon 9, no. 10 (2023): e21073.

[23] J. Puig, G. Blasco, J. Daunis-i-Estadella, et al., “Lower Serum Osteocalcin Concentrations Are Associated With Brain Microstructural Changes and Worse Cognitive Performance,” Clinical Endocrinology 84, no. 5 (2016): 756-763.

[24] C. Luckhaus, B. Mahabadi, B. Grass-Kapanke, et al., “Blood Biomarkers of Osteoporosis in Mild Cognitive Impairment and Alzheimer's Disease,” J Neural Transm (Vienna) 116, no. 7 (2009): 905-911.

[25] Z. Pu, X. Tang, Y. Fei, Q. Hou, Y. Lin, and X. Zha, “Bone Metabolic Biomarkers and Bone Mineral Density in Male Patients With Early-stage Alzheimer's Disease,” Eur Geriatr Med 11, no. 3 (2020): 403-408.

[26] Z. T. Liu, M. H. Liu, Y. Xiong, Y. J. Wang, and X. L. Bu, “Crosstalk Between Bone and Brain in Alzheimer's Disease: Mechanisms, Applications, and Perspectives,” Alzheimers Dement 20, no. 8 (2024): 5720-5739.

[27] C. Shan, D. Zhang, D. N. Ma, et al., “Osteocalcin Ameliorates Cognitive Dysfunctions in a Mouse Model of Alzheimer's Disease by Reducing Amyloid Beta Burden and Upregulating Glycolysis in Neuroglia,” Cell Death Discov 9, no. 1 (2023): 46.

[28] Y. Xuan, L. H. Sun, D. M. Liu, et al., “Positive Association Between Serum Levels of Bone Resorption Marker CTX and HbA1c in Women With Normal Glucose Tolerance,” Journal of Clinical Endocrinology and Metabolism 100, no. 1 (2015): 274-281.

[29] I. Mosialou, S. Shikhel, N. Luo, et al., “Lipocalin-2 Counteracts Metabolic Dysregulation in Obesity and Diabetes,” Journal of Experimental Medicine 217, no. 10 (2020).

[30] S. Cui, F. Xiong, Y. Hong, et al., “APPswe/Abeta Regulation of Osteoclast Activation and RAGE Expression in an Age-dependent Manner,” Journal of Bone and Mineral Research 26, no. 5 (2011): 1084-1098.

[31] W. F. Xia, J. U. Jung, C. Shun, et al., “Swedish Mutant APP Suppresses Osteoblast Differentiation and Causes Osteoporotic Deficit, Which Are Ameliorated by N-acetyl-L-cysteine,” Journal of Bone and Mineral Research 28, no. 10 (2013): 2122-2135.

[32] C. M. Dengler-Crish, M. A. Smith, and G. N. Wilson, “Early Evidence of Low Bone Density and Decreased Serotonergic Synthesis in the Dorsal Raphe of a Tauopathy Model of Alzheimer's Disease,” Journal of Alzheimer's Disease 55, no. 4 (2017): 1605-1619.

[33] J. M. Grewe, P.-R. Knapstein, A. Donat, et al., “The Role of Sphingosine-1-phosphate in Bone Remodeling and Osteoporosis,” Bone Res 10, no. 1 (2022): 34.

[34] K. Fehsel and J. Christl, “Comorbidity of Osteoporosis and Alzheimer's Disease: Is ‘AKT’-ing on Cellular Glucose Uptake the Missing Link?,” Ageing Research Reviews 76 (2022): 101592.

[35] R. Zhou, J. Deng, M. Zhang, H. D. Zhou, and Y. J. Wang, “Association Between Bone Mineral Density and the Risk of Alzheimer's Disease,” Journal of Alzheimer's Disease 24, no. 1 (2011): 101-108.

[36] W. Liang, T. Wei, L. Hu, et al., “An Integrated Multi-omics Analysis Reveals Osteokines Involved in Global Regulation,” Cell metabolism 36, no. 5 (2024): 1144-1163.

[37] X. L. Bu, P. Y. Sun, D. Y. Fan, et al., “Associations of Plasma Soluble CD22 Levels With Brain Amyloid Burden and Cognitive Decline in Alzheimer's Disease,” Science Advances 8, no. 13 (2022): eabm5667.

[38] W.-W. Li, Z. Wang, D.-Y. Fan, et al., “Association of Polygenic Risk Score With Age at Onset and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease in a Chinese Cohort,” Neurosci Bull 36, no. 7 (2020): 696-704.

[39] D.-Y. Fan, J.-M. Jian, S. Huang, et al., “Establishment of Combined Diagnostic Models of Alzheimer's Disease in a Chinese Cohort: The Chongqing Ageing & Dementia Study (CADS),” Transl Psychiatry 12, no. 1 (2022): 252.

[40] C. R. Jack, D. A. Bennett, K. Blennow, et al., “NIA-AA Research Framework: Toward a Biological Definition of Alzheimer's Disease,” Alzheimer's & Dementia: the Journal of the Alzheimer's Association 14, no. 4 (2018): 535-562.

[41] G. M. McKhann, D. S. Knopman, H. Chertkow, et al., “The Diagnosis of Dementia due to Alzheimer's Disease: Recommendations From the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease,” Alzheimers Dement 7, no. 3 (2011): 263-269.

[42] M. S. Albert, S. T. DeKosky, D. Dickson, et al., “The Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease: Recommendations From the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease,” Alzheimers Dement 7, no. 3 (2011): 270-279.

[43] C. R. Jack, D. A. Bennett, K. Blennow, et al., “NIA-AA Research Framework: Toward a Biological Definition of Alzheimer's Disease,” Alzheimers Dement 14, no. 4 (2018): 535-562.

[44] M. L. Gorno-Tempini, A. E. Hillis, S. Weintraub, et al., “Classification of Primary Progressive Aphasia and Its Variants,” Neurology 76, no. 11 (2011): 1006-1014.

[45] K. Rascovsky, J. R. Hodges, D. Knopman, et al., “Sensitivity of Revised Diagnostic Criteria for the Behavioural Variant of Frontotemporal Dementia,” Brain 134, no. 9 (2011): 2456-2477.

[46] S. Gilman, G. K. Wenning, P. A. Low, et al., “Second Consensus Statement on the Diagnosis of Multiple System Atrophy,” Neurology 71, no. 9 (2008): 670-676.

[47] Y. H. Liu, S. S. Jiao, Y. R. Wang, et al., “Associations between ApoEε4 Carrier Status and Serum BDNF Levels-New Insights Into the Molecular Mechanism of ApoEε4 Actions in Alzheimer's Disease,” Molecular Neurobiology 51, no. 3 (2015): 1271-1277.

[48] Y. Cheng, J. R. Ren, J. M. Jian, et al., “Associations of Plasma Angiostatin and Amyloid-β and Tau Levels in Alzheimer's Disease,” Transl Psychiatry 12, no. 1 (2022): 194.

[49] M. C. Carrillo, K. Blennow, H. Soares, et al., “Global Standardization Measurement of Cerebral Spinal Fluid for Alzheimer's Disease: An Update From the Alzheimer's Association Global Biomarkers Consortium,” Alzheimers Dement 9, no. 2 (2013): 137-140.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.